Millions of people around the world struggle with obstructive sleep apnea, a serious sleep disorder that causes breathing to repeatedly stop and start during sleep.
Many people with the condition snore loudly, wake up feeling exhausted, or feel sleepy during the day even after spending many hours in bed.
In severe cases, sleep apnea can increase the risk of heart disease, high blood pressure, stroke, diabetes, memory problems, and even early death.
For years, the most common treatment for obstructive sleep apnea has been CPAP, short for Continuous Positive Airway Pressure. CPAP machines work by pushing air through a mask worn over the nose or mouth to keep the airway open during sleep.
Although CPAP can be very effective, many patients struggle to use it every night. Some people find the mask uncomfortable, noisy, or difficult to sleep with. Others stop treatment completely because they cannot tolerate it.
Now, researchers may have found a much simpler option. A new once-nightly pill called AD109 has shown strong results in a large Phase III clinical trial. The findings were presented at the 2026 ATS International Conference and published in the American Journal of Respiratory and Critical Care Medicine.
The study was called SynAIRgy and involved 646 adults with mild to severe obstructive sleep apnea. All participants either could not tolerate CPAP or chose not to use it. Researchers carried out the trial over six months at 69 medical centers across the United States and Canada.
The new pill works differently from older approaches to sleep apnea treatment. Instead of simply helping people breathe mechanically like a CPAP machine, AD109 targets one of the underlying causes of the disease.
During sleep, the muscles in the throat relax too much in people with obstructive sleep apnea. This allows the airway to narrow or collapse, blocking airflow and interrupting breathing.
AD109 combines two medicines, aroxybutynin and atomoxetine, which work together to help keep throat muscles active during sleep. By improving muscle control, the drug may prevent the airway from collapsing.
Researchers found that patients taking AD109 experienced major improvements in their sleep apnea symptoms. Their apnea-hypoxia index, which measures how many times breathing stops or becomes shallow during sleep, dropped by about 44%. In comparison, people taking a placebo pill improved by only about 18%.
The study also found improvements in oxygen levels during sleep. Sleep apnea often causes repeated drops in blood oxygen, which can put stress on the heart, brain, and other organs. Patients taking AD109 had fewer periods of oxygen deprivation and healthier oxygen levels overall.
More than 40% of patients taking the drug improved enough to move into a less severe sleep apnea category. Even more impressively, about 18% achieved complete disease control during the study period.
Dr. Patrick John Strollo, a sleep medicine specialist at the University of Pittsburgh Medical Center and the lead author of the study, said the results support a growing scientific understanding of sleep apnea. Researchers now believe that problems with throat muscle control play an important role in the disease for many patients.
The benefits of the drug appeared across different patient groups, including people with varying body sizes and different levels of disease severity. This suggests the treatment may work for a broad range of patients.
The researchers also carefully studied safety. The most common side effects included dry mouth, nausea, trouble sleeping, and difficulty urinating. Most side effects were considered mild. However, around 21% of participants stopped taking the medication because of side effects.
Despite this, experts believe the drug could still become an important treatment option, especially for people who cannot use CPAP successfully. Dr. Strollo explained that many patients with obstructive sleep apnea remain untreated today because existing options are difficult to tolerate.
He pointed out that in diseases like asthma, diabetes, or heart disease, doctors would never accept a situation where most patients remain untreated. Yet this still happens with sleep apnea, even though the condition can seriously damage health over time.
The drug has already received Fast Track designation from the U.S. Food and Drug Administration, which is used for promising treatments that address major unmet medical needs. The company developing the drug, Apnimed, has submitted an application seeking approval from the FDA.
Researchers hope the drug may eventually become the first widely available pill designed specifically to treat the underlying causes of obstructive sleep apnea rather than simply managing symptoms.
The findings are exciting because they could represent a major shift in sleep medicine. For many years, treatment choices for sleep apnea have been limited, especially for people who cannot tolerate CPAP machines. A pill that can improve breathing during sleep could make treatment easier and more acceptable for millions of patients.
Still, some important questions remain. While the results are very promising, the study lasted only six months.
Scientists still need more information about the long-term safety of the drug and whether the improvements continue over many years. The fact that one in five participants stopped treatment because of side effects also shows that the medication may not be suitable for everyone.
Even so, the trial marks one of the biggest advances in sleep apnea treatment in many years. If approved, AD109 could help many people sleep better, feel more rested, and lower their risk of serious health problems linked to untreated sleep apnea.
If you care about sleep, please read studies about herb that could help you sleep well at night, and these drugs could lower severity of sleep apnea by one third.
For more health information, please see recent studies that coffee boosts your physical activity, cuts sleep, affects heartbeat, and results showing how to deal with “COVID-somnia” and sleep well at night.
